Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2006

Conditions
ThrombosisVenous ThrombosisCatheter Occlusion
Interventions
DRUG

Alfimeprase

single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD

Trial Locations (18)

24074

Carilion Gynecology/Oncology, Roanoke

33133

Mercy Hospital, Miami

33435

Bethesda Research Center, Boynton Beach

34613

Pasco Hernando Oncology Associates, Brooksville

34652

Pasco Hernando Oncology Associate, New Port Richey

43235

Hematology/Oncology Consultants, Inc., Columbus

44718

Gabrail Cancer Center, Canton

48912

Sparrow Cancer Center, Lansing

49048

Kalamazoo Hematology and Oncology, Kalamazoo

58103

Dakota Cancer Institute, Fargo

61401

Medical and Surgical Specialists, Galesburg

62301

Cancer Center at Blessing Hospital, Quincy

63141

The Center for Cancer Care and Research, St Louis

65109

Comprehensive Cancer Care Clinic, Jefferson City

75230

Texas Oncology, P.A., Dallas

85222

Desert Oasis Cancer Center, Casa Grande

95073

Cancer Research & Prevention Center, Soquel

08903

UMDNJ-Robert Wood Johnson Medical School, New Brunswick

Sponsors
All Listed Sponsors
lead

ARCA Biopharma, Inc.

INDUSTRY

NCT00322270 - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters | Biotech Hunter | Biotech Hunter